JS111 / Suzhou Junjing Biomed, Shanghai Junshi Biosci - LARVOL DELTA

JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations (clinicaltrials.gov) - P1/2 | N=42 | Recruiting | Sponsor: Suzhou Junjing BioSciences Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations (clinicaltrials.gov) - P1/2 | N=42 | Not yet recruiting | Sponsor: Suzhou Junjing BioSciences Co., Ltd.

New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer (clinicaltrials.gov) - P1/2; N=156; Recruiting; Sponsor: Suzhou Junjing BioSciences Co., Ltd.

New P1/2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR

Junshi Bio’s EGFR inhibitor nodded for NSCLC study in China (GBI Health) - "Shanghai-based biotech Junshi Biosciences (HKEX:1877; SSE:688180) announced receipt of a clinical trial approval from the National Medical Products Administration (NMPA) in China for JS111 (APL1898), the firm’s pipeline tyrosine kinase inhibitor (TKI) targeting epidermal growth factor receptor (EGFR) exon20 insertion and other rare mutations. The drug can now be assessed in advanced non-small cell lung cancer (NSCLC)."

Non-US regulatory • Lung Cancer • Non Small Cell Lung Cancer • Oncology

Junshi Biology JS111 Project Obtained Notification of Acceptance of Drug Clinical Trial Application [Google translation] (Eastmoney.com) - "Junshi Biopharmaceutical issued an announcement stating that Suzhou Junjing Biomedical Technology Co., Ltd., which was jointly invested by the company and Weijing Biomedical Technology...received the National Drug Administration. Board approved the issuance of the 'acceptance notice book', EGFR inhibitors uncommon mutant capsules AP-L1898 (item code-named 'JS111') clinical trial application is accepted...The development of JS111 is expected to bring new treatments to cancer patients with EGFR mutations such as EGFRexon20 insertion mutations."

Non-US regulatory • Oncology